

# Chemoradiotherapy in pancreatic carcinoma

Sushmita Pathy,  
Subhash Chander

Department of Radiation  
Oncology, All India Institute Of  
Medical Sciences, Ansari Nagar,  
New Delhi – 110 029, India

## Address for correspondence:

Dr. Sushmita Pathy,  
Department of Radiation  
Oncology, All India Institute of  
Medical Sciences, Ansari Nagar,  
New Delhi – 110 029, India.  
E-mail: drsush\_p@yahoo.co.in

## ABSTRACT

Pancreatic cancer patients present late in their course and surgical resection as a modality of treatment is of limited value. Majority develop loco-regional failure and distant metastasis, therefore, adjuvant therapy comprising of radiotherapy and chemotherapy are useful treatment options to achieve higher loco-regional control. Specialized irradiation techniques like intra-operative radiotherapy that help to increase the total tumor dose have been used, however, controvertible survival benefit was observed. Various studies have shown improved median and overall survival with chemoradiotherapy for advanced unresectable pancreatic carcinoma. The role of new agents such as topoisomerase I inhibitors also needs further clinical investigations.

**Key words:** *Carcinoma, chemoradiation, pancreas*

**DOI:** 10.4103/0971-5851.60049

## INTRODUCTION

Pancreatic carcinoma incidence and mortality rates have steadily increased over the last decade. It is the fourth leading cause of mortality from malignant diseases in United States, and presents particularly difficult management problems. Estimated number of new cases of pancreatic cancer and the deaths resulting from it are 33730 and 32300 respectively in the United States in 2006<sup>[1]</sup> In India the incidence varies from 0.-3.5/100,000 population, according to NCRP Biennial Report.<sup>[2]</sup>

The pancreatic carcinoma is difficult to diagnose. At presentation only 20% of the patients with adenocarcinoma of the pancreas have resectable tumors. Forty per cent of the patients have locally advanced disease while remaining 40% have metastatic disease.<sup>[3-5]</sup> The survival rates in pancreatic adenocarcinoma patients are stuck at abysmally low levels. In patients with resectable disease but positive surgical margins or with locally advanced disease, the median survival time is less than a year following chemoradiation. Two year survival rates range from 20-40% with surgery alone. The overall five-year survival rate is less than four per cent.<sup>[6]</sup> Despite resection, local recurrence and distant metastases occur in up to 50% of patients mostly within liver and peritoneum.<sup>[7,8]</sup>

On the basis of treatment failure patterns, adjuvant irradiation in both preoperative and postoperative setting along with chemotherapy has been used to reduce local recurrence and distant metastases.

The present review focuses on the various adjuvant therapy schedules for pancreatic carcinoma, current treatment principles and future prospects.

## RESECTABLE PANCREATIC CANCER

Recognition of the high rates of local, regional, and metastatic tumor recurrence following a surgical resection has prompted widespread efforts to develop effective adjuvant treatment for pancreatic cancer. Adjuvant chemoradiation in resectable pancreatic cancer has been tried in the past to improve local control and survival. In a prospective randomized trial by Gastrointestinal Tumor Study Group (GITSG)<sup>[9]</sup> the patients, after curative resection, were randomized to adjuvant radiation and chemotherapy versus observation. Twenty two patients were randomized to no adjuvant treatment while 21 to combined therapy consisting of External Beam Radiotherapy (EBRT) and 5 FU. Combined therapy consisted of 40 Gy EBRT given in two courses of 20 Gy/10 fractions each separated by an interval of two weeks. Concomitant 5 FU was administered for three consecutive days at a daily dose of 500mg/m<sup>2</sup> at the beginning of each 20 Gy course. Results indicated a doubling of median and long-term survival (median 20 months vs. 11 months; two years survival 43% vs. 15%). Despite this improvement 71% of patients manifested recidivation, with 50% relapsing in the liver.

Several retrospective studies including those from Mayo Clinic,<sup>[10]</sup> John Hopkins University,<sup>[11]</sup> University of Pennsylvania<sup>[12]</sup> and France<sup>[13]</sup> have confirmed results of GITSG [Table 1].

**Table 1: Adjuvant studies in pancreatic cancer**

Adjuvant study	Study design	EBRT dose (Gy)	Chemotherapy	MS, Months	Comments
Kaiser <i>et al.</i>	22 pts surgery alone	None	None	11	
GITSG (1985)	21 pts to CRT	40	5 FU Bolus	20	
				( <i>P</i> = 0.01)	
Foo <i>et al.</i>	29	45-54	5 FU Bolus	22.8	Improved survival with adjuvant therapy
Mayo Clinic (1993)					
Yeo <i>et al.</i>	53 pts surgery alone	None	None	13.5	
John Hopkins (1997)	99 pts standard	40-45 split course	5 FU Bolus	21	
	21 intensive	50.4-57.6 + liver 23-27	5-FU CI	( <i>P</i> = 0.002)	
				17.5	
Whittington (1991)	33 pts surgery alone	None	None	15	
	10 pts RT alone	45-54	None	15	
	28 pts CRT	45-54	5 FU infusion	15	

EBRT: External beam radiotherapy, MS: Median survival

The Mayo Clinic experience was reviewed for survival and pattern of failure after resection alone and after adjuvant treatment with chemoradiation.<sup>[9,10]</sup> Twenty nine patients underwent curative resection followed by adjuvant radiation and 5 FU chemotherapy. The median RT dose was 54 Gy; the radiation portals encompassed the tumor bed and regional node. Seventeen out of 29 patients received continuous course treatment, 27 of 29 patients received concomitant bolus 5 FU chemotherapy. Median survival was 22.8 months, with a two-year survival of 48%, similar to results achieved with adjuvant therapy in GITSG study, however, high incidence of hepatic failure and peritoneal seeding was also observed.<sup>[10,11]</sup>

Yeo *et al.* in a prospective study evaluated two difference postoperative adjuvant chemoradiation to no adjuvant therapy. 174 patients underwent pancreaticoduodenectomy and were offered standard therapy with external beam radiotherapy (EBRT) and 5 FU Bolus, intensive therapy EBRT and 5-FU infusion with prophylactic hepatic irradiation or no adjuvant therapy. The authors concluded adjuvant chemoradiation significantly improves survival intensive therapy offered no survival advantage.<sup>11</sup> Yeo and coworkers performed analysis of patients who underwent pancreaticoduodenectomy with or without adjuvant chemoradiation for cancer of head of pancreas at Johns Hopkins University Hospital.<sup>[14]</sup> In the initial study, statistically significant difference in survival was observed among those patients with positive margins compared with negative margins. Postoperative adjuvant chemotherapy and radiation therapy together with negative nodal status and tumor diameter smaller than 3cm significantly favored long term survival. The EORTC and GITSG<sup>[15]</sup> evaluated patients with early pancreatic carcinoma. Patients were randomized to EBRT plus concurrent 5 FU or observation alone after surgical resection. However, 20% of the patients did not receive any treatment due to postoperative complications. The two-year overall survival rates were 23% and 27% for those randomized to observation and those to adjuvant therapy. The trial had many flaws as it had a

long accrual period (8 years) and very early stage cases were primarily enrolled in the trials.

Preliminary analysis of the European study group for pancreatic cancer trials -1 (ESPAC-1) comparing adjuvant chemotherapy (weekly 5 FU and Folinic acid) and RT-40 Gy with chemotherapy alone, showed no benefit for chemoradiation.<sup>[16]</sup>

A further publication has provided upgraded information of this trial. For the patients who received chemoradiotherapy the five-year survival rate was estimated to be 10% whereas among patients who were not given chemoradiotherapy it was 20% (*P* = 0.05). The five-year survival rate was 21% among patients who received chemotherapy and eight per cent among patients who did not receive chemotherapy (*P* = 0.009). Thus adjuvant chemotherapy was associated with a significant survival benefit in patients with resected pancreatic cancer, yet adjuvant chemoradiotherapy produced a deleterious effect on survival.<sup>[17]</sup>

It is difficult to draw conclusions about the role of RT in the treatment of pancreatic carcinoma from current randomized trials due to use of split course radiotherapy, low RT dose and incomplete therapy. Thus the traditional therapy for resectable tumor continues to be pancreaticoduodenectomy followed by adjuvant radiation and concomitant 5 FU based chemotherapy.

## RADIATION THERAPY

The GITSG trial discussed above, did not demonstrate a significant difference in causes of death or sites of treatment failure between the various patient groups randomized to observation or adjuvant chemoradiotherapy and radiotherapy. High local failures were observed in view of low radiation dose.

Specialized irradiation techniques that increase the dose to the tumor volume have been used to improve local tumor

control without increasing normal tissue morbidity. IORT allows direct visualization and delivery of high doses of radiation to the tumor bed during the operation, a facility not available with conventional radiation. Sensitive normal structures may be moved away from the radiation field. Intraoperative radiotherapy does not necessarily improve the survival even though local recurrences may be observed less often.

NCI conducted a trial in which 11 patients with resectable disease were randomized to IORT (20 Gy) or EBRT (45-55 Gy) and additional four patients of stage I received no further treatment.<sup>[18]</sup> Median survival was 18 months. Local recurrence was observed in 47% and regional recurrence in 47% instances. Intrabdominal metastases consisting of peritoneal seeding occurred in 45%, liver metastasis in 47% and distant metastases in 62%.

Similar results were reported by Fossati *et al.*<sup>[19]</sup> in their review of 33 patients who underwent resection for pancreatic carcinoma plus IORT with or without EBRT with or without chemotherapy. The local recurrence rate was significantly lower with IORT (25% vs. 55.8%); overall survival however was not significantly different in the IORT group compared with control group.

Zerbi and colleagues<sup>[20]</sup> also reported on use of IORT in patients with operable pancreas cancer. IORT (12.5 to 20 Gy) was delivered after surgery in 43 patients. Forty seven additional patients underwent resection alone. Local recurrence was significantly decreased in IORT group (27% vs. 56%,  $P < 0.01$ ). Thus IORT may benefit patients with resectable disease, but has little impact on survival<sup>[21,22]</sup> However with the advances of systemic therapy, this may confer a significant benefit in long-term outcome. Yamaguchi *et al.* found that only the combination of IORT with external radiotherapy led to some betterment in the short-term results of patients with resectable pancreatic carcinoma. These authors felt it was advisable to give external radiotherapy after pancreatectomy and IORT.<sup>[23]</sup>

More recently, Japanese workers have reported a study evaluating hyperfractionated accelerated radiotherapy (HART) and 5-FU and cisplatin in patients with unresectable pancreatic carcinoma. HART was given as 1.5 Gy twice daily doses, separated by six hours for five days a week (total dose of 45 Gy). They observed that 35% patients showed partial response, 50% remained stable while another 15% had local progressive disease. The authors found the toxicity to be well tolerated and local efficacy of the treatment was as per their expectations.<sup>[24]</sup>

## CHEMOTHERAPY

Whittington *et al.*<sup>[12]</sup> in a retrospective analysis of 70 patients with pancreatic cancer divided therapy to no adjuvant therapy (33 patients), postoperative Rtalone or plus bolus 5 FU chemotherapy (19 patients) 8/19 patients received bolus 5 FU and 96 hour infusion 5 FU chemotherapy with RT (20 patients). Median survival was similar; however, three-year survival was significantly improved with chemo-sensitized irradiation.

Gemcitabine is also a potent radiation sensitizer of human pancreatic cancer cells and was found to be superior to bolus 5 FU in a prospective randomized trial.<sup>[25]</sup> Trials are underway to evaluate its role in the preoperative setting. A large phase III trial with 5 FU was performed by Eastern cooperative Oncology Group (ECOG)<sup>[26]</sup> comparing single agent gemcitabine (162 pts) with gemcitabine plus 5 FU (160 pts) median survival 6.7 months combination arm and 5.4 months with single agent.

In a multicenter study, Rocha Lima *et al.*<sup>[27]</sup> compared the overall survival associated with Irinotecan and gemcitabine (IRINOGEN) versus Gemcitabine (GEM) a single agent concluded IRINOGEN safely improved tumour response rate compared with GEM, but did not alter overall survival.

Heinemann *et al.* compared Gemcitabine and cisplatin combination with Gemcitabine alone. Combination therapy arm was accompanied by a prolonged median progression-free survival (5.3 months vs. 3.1 months). The median overall survival was also prolonged in the former group. Albeit tumor response rates were comparable in the two treatment arms (10.2% vs. 8.2%).<sup>[28]</sup> These studies are summarized in Table 2.

## PREOPERATIVE VS. POSTOPERATIVE THERAPY

The timing of adjuvant therapy has been a subject of debate. Preoperative radiation therapy offers the

**Table 2: Chemotherapy in pancreatic carcinoma**

Authors	No. of patients	Study design	Median survival	Comments
Heinemann <i>et al.</i> (2006)	195	Gemcitabine Gemcitabine + cisplatin	6 7.5	Combination are / was more effective no statistical significance
Berlin <i>et al.</i>	160	Gemcitate + 5FU	6.7	
ECOG (2002)	162	Gemcitabine	5.4	
Rocha Lima (2004)	360	Gem Gem + Irinotecan	6.6 6.3	Irinotecan safety improved tumor response but did not alter overall survival

advantage of tumor down staging, decrease in the risk of tumor seeding during surgery and avoiding treatment delays in postoperative setting due to postoperative complications.

In a trial conducted by ECOG, preoperative 5 FU, Mitomycin C and EBRT were administered in patients with resectable tumors. Two years survival was 27%.<sup>[29,30]</sup>

Pendurthi *et al.*<sup>[31]</sup> while comparing preoperative and postoperative chemoradiation, observed no significant difference in survival or local control; however, treatment delay of more than 60 days was observed in postoperative group in 22% patients. Quite recently, Massucco *et al.* admitted that the indications of pancreatic resection subsequent to chemo-radiation are not described clearly. These workers subjected 28 patients with locally advanced pancreatic carcinoma to Gemcitabine-based chemoradiotherapy. Patients showing partial response or a stable disease were operated upon. The results thus obtained were compared to another group of 44 cases, resected for localized cancer (irrespective of adjuvant treatment status). Median survival was 15.4 months and 14 months respectively. It was concluded that transition of an unresectable lesion to a resectable one is a rarity in patients having pancreatic cancer.<sup>[32]</sup>

### PROPHYLACTIC LIVER IRRADIATION

More than half of the patients treated with surgery and adjuvant therapy develop hepatic metastases. Phase I-II trials evaluating prophylactic hepatic irradiation was conducted. Komaki *et al.*<sup>[33]</sup> from Medical College of Wisconsin conducted a pilot study in which 15 patients were treated with EBRT consisting of 61.2 Gy to pancreas and 23.4 Gy to liver, 5 FU was given with EBRT and for 12 months after RT. Two years disease free survival was 46.7%. Two patients had hepatic metastasis as first site of failure.

Evans *et al.*<sup>[34]</sup> in an analysis of 11 patients treated with 50.4 Gy external beam RT to the pancreas with concurrent continuous infusion of 5 FU and hepatic irradiation up to 23.4 Gy on day 8 to 21, resectable patients were taken up for pancreato-duodenectomy and additional 10 Gy was delivered as IORT to the tumor bed. The study suggested the lack of benefit to prophylactic hepatic irradiation and was terminated in view of two treatment related deaths.

### UNRESECTABLE PANCREATIC CANCER

Approximately 40-50% of the tumors are classified as locally advanced disease and their median survival is 3-5

months.<sup>[35]</sup> As primary surgical approach is not possible in these cases, systemic treatment alone or in combination with radiotherapy is necessary, recent research has been focused on intensification of RT and chemotherapy.

O'Conner *et al.* reported 77 patients subjected to attempted surgical resection and IORT for pancreatic or periampullary adenocarcinoma. Twenty-four patients had unresectable tumors and went through surgical bypass and IORT. Patients with unresectable disease treated with bypass and IORT had a median survival of 11 months only. The authors concluded that IORT is well tolerated. They observed that patients with periampullary adenocarcinoma had a better prognosis than those with pancreatic adenocarcinoma. Obviously the patients with unresectable pancreatic disease fared worse.<sup>[36]</sup>

### CHEMORADIATION

Combined chemoradiation therapy for unresectable carcinoma of the pancreas was first studied at Mayo clinic.<sup>[37]</sup> Thirty two patients with unresectable adenocarcinoma of pancreas were randomized to receive EBRT (35 to 40 Gy with four weeks) with or without 5 FU based chemotherapy. Results showed a statistically significant improvement in median survival with addition of 5 FU, 10.4 months vs 6.3 months. GITSG<sup>[38,39]</sup> published results of three arm trial in which patients were randomized to receive external beam RT to 60 Gy alone, external beam RT to 40 Gy plus bolus 5 FU or external beam RT 60 Gy plus bolus 5 FU. Patients treated with combined modality therapy had an improvement in median survival (42 vs. 22 weeks  $P<0.01$ ) compared with those treated with RT alone. No significant difference was noted in outcome with treatment by 40 Gy or 60 Gy.

On the basis of the results of this study, combined chemoradiotherapy became the standard treatment in locally unresectable pancreatic cancer. A randomized prospective trial evaluating 5 FU alone versus 5 FU plus EBRT (40 Gy) was performed by ECOG.<sup>[40]</sup> Ninety one patients were entered. Median survival was 8.2 months for patients receiving chemotherapy alone and 8.3 months for combined modality therapy.

The benefit of chemo-irradiation was studied by GITSG<sup>[41]</sup> and it was observed that both median and overall survival rates were improved with addition of radiotherapy to chemotherapy. The treatment schedules were Streptozocin, Mitomycin and 5-fluorouracil (SMF) versus radiation and 5-fluorouracil followed by SMF combination chemotherapy. Median survival for the combined-modality treatment was 42 weeks. This is better than the 32 weeks median survival with chemotherapy alone.

Hyperfractionated radiotherapy was evaluated in a pilot study by Gastrointestinal Tumor Study Group. EBRT consisting of 50.4 Gy (1.2 Gy twice daily, four to six hours apart) was given along with 5 FU on the first three and last three days of radiation therapy. Further chemotherapy was given using Streptozotocin and Mitomycin and 5 FU. One-year survival rate was 39% and median survival was 35 weeks.<sup>[42]</sup>

Abe and colleagues<sup>[43]</sup> published the largest experience with Intraoperative Radiotherapy (IORT) for unresectable pancreatic carcinoma. One hundred and three patients were treated with surgery plus EBRT, intraoperative radiotherapy or combination of both EBRT consisting of 55-60 Gy and IORT ranging from 25-40 Gy depending on the tumor site. Median survival was nine months vs. 12 months vs. 5.5 months to surgery plus EBRT, IORT plus EBRT and IORT or surgery alone respectively. Ma et studied the effect of Interferon- $\alpha$  for its synergistic effects with chemoradiation in pancreatic adenocarcinoma and concluded that IFN- $\alpha$  has direct cytotoxic effects acting as radiosensitizer and controls tumor re-growth after cisplatin therapy.<sup>[44]</sup>

Ghassan *et al.* treated 175 patients having locally advanced or metastatic pancreatic adenocarcinoma with Exatecan plus Gemcitabine. Exatecan Mesylate is a hexacyclic, water-soluble, topoisomerase-1 inhibitor. Another 174 patients were given Gemcitabine alone. The median survival time was 6.7 and 6.2 months respectively ( $P = 0.52$ ). They concluded that Exatecan along with Gemcitabine was not found superior to Gemcitabine alone.<sup>[45]</sup>

## QUALITY OF LIFE CONSIDERATIONS

Neoptolemos *et al.*<sup>[17]</sup> in the European Study Group for Pancreatic Cancer Trials1 evaluated quality of life in these patients. Questionnaires regarding the quality of life were filled by 152 of the 289 patients. There were no significant differences in the post-resection quality of life within 12 months between patients who received chemotherapy and those not receiving chemotherapy ( $P=0.75$ ) and also between the patients who received chemoradiotherapy and those who did not receive chemoradiotherapy ( $P=0.17$ ).

## CONCLUSION

Pancreatic carcinoma is a leading cause of death. These tumors present late in their course and less than 20% are amenable to surgical resection. The treatment of pancreatic cancer continues to be a challenge to the oncologists.

Emerging techniques in the fields of surgery, radiotherapy, chemotherapy and immunotherapy offer hope for greater

locoregional control, survival and quality of life for this highly fatal disease. There is a need for improvement in local control for both resectable and unresectable disease, and the evolution of three-dimensional and intensity modulated techniques offers the potential for more precise targeting of the primary lesion and thus may allow safe escalation of tumor dose.

Adjuvant chemotherapy with Gemcitabine has recently demonstrated better survival outcomes

Newer chemotherapeutic drugs including topoisomerase I inhibitors, thymidylate synthetase inhibitors and angiogenesis inhibitors, matrix metalloproteinase inhibitors, interleukin 2 may have the potential to counter the high regional and distant relapse.<sup>[46]</sup>

Further understanding of pancreatic tumor biology may lead to optimized treatment selection. Advances in imaging and molecular genetics will help in early diagnosis and more effective novel treatment.

## REFERENCES

1. American Cancer Society.: Cancer Facts and Figures 2006. Atlanta, Ga: American Cancer Society, 2006.
2. National Cancer Registry Program. Biennial report. Population based cancer registries 1988-89. An epidemiological study. Cancer Incidence 1992. p. 10-4.
3. Allema JH, Reinders ME, van Gulik TM, Koelemay MJ, van Leeuwen DJ, de Wit LT, *et al.* Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. *Cancer* 1995;75:2069.
4. Lowy AM, Leach SD. Adjuvant/neoadjuvant chemoradiation for gastric and pancreatic cancer. *Oncology* 1999;5:121.
5. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy: 118 consecutive resections without an operative mortality. *Ann Surg* 1990;211:447.
6. Kleeff J, Michalski C, Friess H, Buchler MW. Pancreatic cancer: from bench to 5-year survival. *Pancreas* 2006;33:111.
7. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma: Clinicopathologic analysis of 5-year survivors. *Ann Surg* 1996;223:273.
8. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma (discussion). *Am J Surg* 1993;16:72.
9. Kalsner MH, Ellenberg SS. Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. *GITSG. Arch Surg* 1985;120:899.
10. Foo ML, Gunderson LL, Nagorney DM, McLlraith DC, van Heerden JA, Robinow JS, *et al.* Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation + 5 FU. *Int J Pediatr Oncol Biol Phys* 1993;26:483-9.
11. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, *et al.* Pancreaticoduodenectomy resection for pancreatic adenocarcinoma: Postoperative adjuvant radiotherapy improves survival. A prospective single institute experience. *Ann Surg* 1997;225:621-33.
12. Whittington R, Bryer MP, Haller DG, Solin LJ, Rosato EF. Adjuvant therapy of resected adenocarcinoma of the pancreas. *Int J Radiat Oncol Biol Phys* 1991;21:1137-43.

13. Bosset JF, Pavy JJ, Gillet M, Mantion G, Pelissier E, Schraub S. Conventional external irradiation alone as adjuvant treatment in resectable pancreatic cancer. Results of a prospective study. *Radiother Oncol* 1992;24:191-4.
14. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, *et al.* Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. *Ann Surg*. 1995 Jun;221(6):721-31; discussion 731-3. PubMed PMID: 7794076; PubMed Central PMCID: PMC1234702.
15. Klinkenbijn JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, *et al.* Adjuvant radiotherapy and 5 FU after curative resection of cancer of the pancreas and periampullary region. *Ann Surg* 1999;230:776-82.
16. Neoptolemos JP, Dunn JA, Moffitt DD. ESPAC-1 interim results. A European, randomized study to assess the role of adjuvant chemotherapy (5 FU + Folinic Acid) and adjuvant chemoradiation (40 Gy + 5 FU) in resectable pancreatic cancer. *Proc Am Soc Clin Oncol* 2000;19:238a.
17. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, *et al.* A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. *N Engl J Med* 2004;350:1200-10.
18. Johnstone PA, Sindelar NF. Patterns of disease recurrence following definitive therapy and adenocarcinoma of the pancreas using surgery and adjuvant radiotherapy: correlation of clinical trial. *Int J Radiat Oncol Biol Phys* 1993;27:831-4.
19. Fossati V, Cattaneo GM, Zerbi A, Galli L, Bordogna G, Reni M, *et al.* The role of IORT by electron beam and combination of adjuvant chemotherapy and external radiotherapy in carcinoma of pancreas. *Thorax* 1995;81:23-31.
20. Zerbi A, Fossati V, Parolini D, Carlucci M, Balzano G, Bordogna G, *et al.* Intraoperative radiation therapy adjuvant to resection in treatment of pancreatic cancer. *Cancer* 1994;73:2930-5.
21. Gunderson LL, Haddock MG, Burch P, Nagorney D, Foo ML, Todoroki T. Future role of radiotherapy as a component of treatment in biliopancreatic cancers. *Ann Oncol* 1999;10:291-5.
22. Sindelar WF, Kinsella TJ. Studies of intraoperative radiotherapy in carcinoma of the pancreas. *Ann Oncol* 1999;10:226-30.
23. Yamaguchi K, Nakamura K, Kobayashi K, Nakano K, Konomi H, Mizumoto K, *et al.* ERT following IORT improves survival of patients with resectable pancreatic cancer *Hepatogastroenterology* 2005;52:1244-9.
24. Tsujie M, Nakamori S, Tanaka E, Nagano H, Umeshita K, Dono K, *et al.* Phase I/II trial of hyperfractionated accelerated chemoradiotherapy for unresectable advanced pancreatic cancer. *Jpn J Clin Oncol* 2006;36:504-10.
25. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, *et al.* Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer. A randomized trial. *J Clin Oncol* 1997;15:2043-13.
26. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2292. *J Clin Oncol* 2002;20:3270-5.
27. Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, *et al.* Iritnotecan and gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patient with locally advanced or metastatic pancreatic cancer despite increased tumor response rates. *J Clin Oncol* 2004;22:3776-83.
28. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekeas H, Rost A, *et al.* Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. *J Clin Oncol* 2006;24:3946-52.
29. Hoffman JP, McGlenn CJ, Szarka C. A phase I study of preoperative gemcitabine with radiation therapy followed by postoperative gemcitabine for patients with localized resectable pancreatic adenocarcinoma. *Proc Am Soc Clin Oncol* 1998;17:283.
30. Hoffman JP, Weese JL, Solin LJ, Engstrom P, Agarwal P, Barber LW, *et al.* A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. *Am J Surg* 1995;169:71-7.
31. Pendurthi TK, Hoffman JP, Ross E, Johnson DE, Eisenberg BL. Preoperative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma. *Am Surg* 1998;64:686-92.
32. Massucco P, Capussotti L, Magnino A, Sperti E, Gatti M, Muratore A, *et al.* Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: Analysis of perioperative outcome and survival. *Ann Surg Oncol* 2006; 13:1201-8.
33. Komaki R, Hansen R, Cox JD, Wilson JF. Phase I, II study of prophylactic hepatic irradiation with local irradiation and systemic chemotherapy for adenocarcinoma and pancreas. *Int J Radiat Oncol Biol Phys* 1988;15:1447-52.
34. Evans DB, Abbruzzese JL, Cleary KR, Buchholz DJ, Fenoglio CJ, Collier C, *et al.* Preoperative chemoradiation for adenocarcinoma of the pancreas: Excessive toxicity of prophylactic hepatic irradiation. *Int J Radiat Oncol Biol Phys* 1995;33:913-8.
35. Warshaw AL, Fernández-del Castillo C. Pancreatic carcinoma. *N Engl J Med* 1992;326:455-65.
36. O'Connor JK, Sause WT, Hazard LJ, Belnap LP, Noyes RD. Survival after attempted surgical resection and intraoperative radiation therapy for pancreatic and periampullary adenocarcinoma. *Int J Radiat Oncol Biol Phys* 2005;63:1060-6.
37. Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA. Combined 5 FU and supervoltage RT for locally unresectable GI cancer. *Lancet* 1969;2:865-7.
38. Gastrointestinal tumor study group. A multi-institutional comparative trial of radiation therapy alone and in combination with 5 FU for locally unresectable pancreatic carcinoma. *Ann Surg* 1987;189:205-8.
39. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, *et al.* Therapy of locally unresectable pancreatic carcinoma. A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5 FU) and high dose radiation + 5 FU cancer 1981;48:1705-10.
40. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of stomach and pancreas: A randomized comparison of 5 FU alone with radiation plus concurrent maintenance 5 FU. An ECOG study. *J Clin Oncol* 1985;3:373-8.
41. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of pancreas: Comparison of combined modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. *J Natl Cancer Inst* 1988;80:751-5.
42. Seydel HG, Stablein DM, Leichman LP, Kinzie JJ, Thomas PR. Hyperfractionated radiation and chemotherapy for unresectable localized adenocarcinoma of the pancreas. The Gastrointestinal Tumor Study Group experience. *Cancer* 1990;65:1478-82.
43. Abe M, Shibamoto Y, Ono K, Takahashi M. Intraoperative radiation therapy for carcinoma of the stomach of pancreas. *Front Radiat Ther Oncol* 1991;25:258-69.
44. Ma JH, Patrut E, Schmidt J, Knaebel HP, Buchler MW, Marten A. Synergistic effects of interferon- $\alpha$  in combination with chemoradiation on human pancreatic adenocarcinoma. *World J Gastroenterol* 2005;11:1521-8.
45. Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyan NS, *et al.* Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. *J Clin Oncol* 2006;24:4441-7.
46. Touroutoglou N, Padzur R. Thymidylate synthase inhibitors. *Clin Cancer Res* 1996;2:227-43.

**Source of Support:** Nil. **Conflict of Interest:** None declared.